Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin.
Rebecca W ZengJie Ning YongDarren J H TanClarissa E FuWen Hui LimJieling XiaoKai En ChanCaitlyn TanXin Lei GohDouglas CheeNicholas Li-Xun SynEunice X TanMark Dhinesh MuthiahCheng-Han NgNobuharu TamakiSung Won LeeBeom Kyung KimMindie H NguyenStephen CaldwellDaniel Q HuangPublished in: Alimentary pharmacology & therapeutics (2023)
Although statin and aspirin use were associated with reduced HCC risk, only statin use was significant in subgroup analyses accounting for concurrent medications. Metformin use was not associated with reduced HCC risk. These data have implications for future clinical trial design.
Keyphrases
- cardiovascular disease
- clinical trial
- systematic review
- low dose
- coronary artery disease
- cardiovascular events
- antiplatelet therapy
- type diabetes
- electronic health record
- randomized controlled trial
- meta analyses
- squamous cell carcinoma
- study protocol
- big data
- current status
- radiation therapy
- atrial fibrillation
- phase ii
- rectal cancer
- anti inflammatory drugs